NCT02531217View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 13, 2015

Primary Completion Date

May 26, 2016

Study Completion Date

May 26, 2016

Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
BIOLOGICAL

ATYR1940

Concentrate for solution for infusion

Trial Locations (3)

43210

aTyr Pharma Investigative Site, Columbus

00168

aTyr Pharma Investigative Site, Rome

Unknown

aTyr Pharma Investigative Site, Nijmegen

All Listed Sponsors
lead

aTyr Pharma, Inc.

INDUSTRY

NCT02531217 - Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension | Biotech Hunter | Biotech Hunter